文献速递淋巴瘤

高级别B细胞淋巴瘤非特指型:一项多机构回顾性研究

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
PubMed 文献 · Blood Adv · 2023-01-01

这项多机构回顾性研究分析了160例高级别B细胞淋巴瘤非特指型(HGBL-NOS)患者的特征与结局。肿瘤具有异质性,多数为生发中心B细胞免疫表型,常见分期IV、乳酸脱氢酶升高。DA-EPOCH-R与R-CHOP等方案在完全缓解率、无进展生存和总生存上无显著差异。完全缓解率69%,2年无进展生存55.2%,总生存68.1%。

要点

  • HGBL-NOS肿瘤异质性高:83%为生发中心B细胞免疫表型,37%为双表达免疫表型。
  • DA-EPOCH-R与R-CHOP等方案在完全缓解率、无进展生存和总生存上无显著差异。
  • 不良体能状态、乳酸脱氢酶>3倍正常上限和双表达免疫表型是PFS和OS的主要预后因素。

核心结论

  • HGBL-NOS患者预后不佳,完全缓解率69%,2年无进展生存55.2%,2年总生存68.1%。
  • DA-EPOCH-R与R-CHOP等方案在完全缓解率、无进展生存和总生存上无显著差异。
  • 需要改进诊断标准和超越剂量密集化疗的治疗方法以克服HGBL-NOS的不良预后。

研究设计与样本

  • 多机构回顾性研究,纳入160例高级别B细胞淋巴瘤非特指型(HGBL-NOS)患者。

主要发现

  • 83%患者为生发中心B细胞免疫表型,37%为双表达免疫表型,28%有MYC重排,13%有BCL2重排,11%有BCL6重排。
  • 多数患者表现为IV期疾病、高血清乳酸脱氢酶和其他高风险临床因素。
  • 最常用一线方案包括DA-EPOCH-R(43%)、R-CHOP(33%)或其他强化化疗方案。
  • 完全缓解率69%,2年无进展生存55.2%,2年总生存68.1%。
  • 多变量模型中,无进展生存和总生存的主要预后因素为不良体能状态、乳酸脱氢酶>3倍正常上限和双表达免疫表型;年龄>60岁或MYC重排无预后意义,TP53改变患者无进展生存极差。

关键数值与推荐

  • HGBL-NOS定义为具有高级别形态学特征且缺乏MYC重排伴BCL2和/或BCL6重排(「双打击」)。
  • 完全缓解率69%,2年无进展生存55.2%,2年总生存68.1%。
  • DA-EPOCH-R与R-CHOP等方案在完全缓解率、无进展生存和总生存上无显著差异。
  • MYC重排的存在不能预测DA-EPOCH-R相比R-CHOP有更好的无进展生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zayac AS, Landsburg DJ, Hughes ME, et al. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023. PMID: 37171397. doi:10.1182/bloodadvances.2023009731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。